Zimmer Biomet Holdings Inc

Zimmer Biomet’s Q1 2026 earnings hit mixed results, with tech revenue up but margins pressured; analysts slash forecasts and stock drops to a 13‑year low.

Zimmer Biomet’s Q3 earnings miss and cancelled emerging‑market orders trigger a 15% stock drop and two shareholder‑rights investigations, highlighting risks for investors.

Zimmer Biomet faces a legal battle over a failed ERP project, yet its strong orthopedic portfolio and investor resilience keep long‑term value intact.

Zimmer Biomet Holdings Inc. navigated a tumultuous week in the financial markets, with its stock reflecting broader market anxieties and specific corporate challenges, amidst a backdrop of financial guidance updates and strategic ambitions.

Zimmer Biomet Holdings Inc. is navigating a complex financial landscape, with its stock price fluctuating due to earnings guidance adjustments and acquisition-related costs, despite its strategic ambitions for innovation and market leadership.

Zimmer Biomet Holdings Inc. has reported mixed financial updates, with a lowered profit forecast offset by strong first-quarter earnings and a bold vision for future growth and innovation.